Tamara A Sutfin

Learn More
OBJECTIVE The ability of the potent cholesteryl ester transfer protein (CETP) inhibitor torcetrapib (CP-529,414) to raise high-density lipoprotein cholesterol (HDL-C) levels in healthy young subjects was tested in this initial phase 1 multidose study. METHODS AND RESULTS Five groups of 8 subjects each were randomized to placebo (n=2) or torcetrapib (n=6)(More)
Imipramine (IMI) and its active metabolites, desipramine (DMI), 2-hydroxyimipramine (2-OH-IMI), and 2-hydroxydesipramine (2-OH-DMI), were assayed by high pressure liquid chromatography in the serum and urine of 14 depressed patients after 1 week of twice-daily treatment with 100 mg of IMI. The concentrations of the glucuronide conjugates of(More)
Single oral and intramuscular (i.m.) doses of imipramine (IMI) were administered to four normal males. Serum and urine concentrations of IMI, desipramine (DMI) and their unconjugated 2-hydroxy metabolites were measured by high-pressure liquid chromatography (HPLC). Urinary conjugated 2-hydroxy metabolites were also measured after enzyme hydrolysis. Computer(More)
Six patients are described who achieved very high plasma concentrations of imipramine and desipramine during chronic therapy with usual doses. Side effects were minimal. Speculation as to apparent tolerance includes the presence of low metabolite concentrations. Plasma concentration monitoring may be indicated to identify the occasional patient who achieves(More)
  • 1